Stockscreener 앱 받기
0.28
0.89%
-0.0887
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire
NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan
NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq
NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World
NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo
NKGen Biotech Delays Annual Report Filing - TipRanks
NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq
NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire
Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire
NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire
Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan
NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa
NKGen Biotech secures $5 million convertible loan - Investing.com India
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks
NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India
NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire
NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan
NKGen Biotech, Inc. SEC 10-Q Report - TradingView
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
2.33%
1.09%
자본화:
|
볼륨(24시간):